Výsledky vyhledávání - Stochastic expansion from cell to cell algorithm

Upřesnit hledání
  1. 1
  2. 2

    Autoři: Liu G Liu S Zhang C a další

    Zdroj: Bulletin of mathematical biology [Bull Math Biol] 2025 Jul 25; Vol. 87 (9), pp. 116. Date of Electronic Publication: 2025 Jul 25.

    Způsob vydávání: Journal Article

    Informace o časopise: Publisher: Springer Country of Publication: United States NLM ID: 0401404 Publication Model: Electronic Cited Medium: Internet ISSN: 1522-9602 (Electronic) Linking ISSN: 00928240 NLM ISO Abbreviation: Bull Math Biol Subsets: MEDLINE

  3. 3
  4. 4
  5. 5

    Autoři: Kylies D Heil HS Vesga AG a další

    Zdroj: Nature protocols [Nat Protoc] 2025 Jul 02. Date of Electronic Publication: 2025 Jul 02.

    Způsob vydávání: Journal Article; Review

    Informace o časopise: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101284307 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-2799 (Electronic) Linking ISSN: 17502799 NLM ISO Abbreviation: Nat Protoc Subsets: MEDLINE

  6. 6
  7. 7

    Autoři: Wang J Ye F Chai H a další

    Zdroj: Science China. Life sciences [Sci China Life Sci] 2025 May; Vol. 68 (5), pp. 1226-1282. Date of Electronic Publication: 2024 Dec 20.

    Způsob vydávání: Journal Article; Review

    Informace o časopise: Publisher: Science China Press, co-published with Springer Country of Publication: China NLM ID: 101529880 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1869-1889 (Electronic) Linking ISSN: 16747305 NLM ISO Abbreviation: Sci China Life Sci Subsets: MEDLINE

  8. 8

    Autoři: Ventre E Espinasse T Bréhier CE a další

    Zdroj: Journal of mathematical biology [J Math Biol] 2021 Nov 05; Vol. 83 (5), pp. 59. Date of Electronic Publication: 2021 Nov 05.

    Způsob vydávání: Journal Article; Research Support, Non-U.S. Gov't

    Informace o časopise: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7502105 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1416 (Electronic) Linking ISSN: 03036812 NLM ISO Abbreviation: J Math Biol Subsets: MEDLINE

  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

    Zdroj: Del Core, L, Pellin, D, Wit, E C & Grzegorczyk, M A 2023, 'A mixed-effects stochastic model reveals clonal dominance in gene therapy safety studies', Bmc Bioinformatics, vol. 24, no. 1, 228.

    URL: https://research.rug.nl/en/publications/e255622f-b0f6-468a-ac3d-0fe768e736e7
    https://doi.org/10.1186/s12859-023-05269-1
    https://hdl.handle.net/11370/e255622f-b0f6-468a-ac3d-0fe768e736e7
    https://pure.rug.nl/ws/files/717097816/s12859-023-05269-1.pdf
    https://www.scopus.com/pages/publications/85160903869
    info:eu-repo/semantics/altIdentifier/doi/10.1186/s12859-023-05269-1
    info:eu-repo/semantics/altIdentifier/pmid/37268887
    info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/11370/e255622f-b0f6-468a-ac3d-0fe768e736e7
    info:eu-repo/semantics/altIdentifier/pissn/1471-2105
    info:eu-repo/semantics/altIdentifier/eissn/1471-2105

  16. 16

    Zdroj: Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours Using the Quadratic Phenotypic Optimization Platform (QPOP) and an Artificial Intelligence-based Platform (CURATE.AI)
    Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, Grace M, Dricot A, Askenazi M, Tavares M, Pevzner SJ, Abderazzaq F, Byrdsong D, Carvunis AR, Chen AA, Cheng J, Correll M, Duarte M, Fan C, Feltkamp MC, Ficarro SB, Franchi R, Garg BK, Gulbahce N, Hao T, Holthaus AM, James R, Korkhin A, Litovchick L, Mar JC, Pak TR, Rabello S, Rubio R, Shen Y, Singh S, Spangle JM, Tasan M, Wanamaker S, Webber JT, Roecklein-Canfield J, Johannsen E, Barabasi AL, Beroukhim R, Kieff E, Cusick ME, Hill DE, Munger K, Marto JA, Quackenbush J, Roth FP, DeCaprio JA, Vidal M. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature. 2012 Jul 26;487(7408):491-5. doi: 10.1038/nature11288.
    Chandarlapaty S. Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov. 2012 Apr;2(4):311-9. doi: 10.1158/2159-8290.CD-12-0018. Epub 2012 Mar 22.
    Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012 Apr 1;26(7):641-50. doi: 10.1101/gad.186965.112.
    Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986 Jan;70(1):163-9. No abstract available.
    Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 1;23(10):2191-200. doi: 10.1200/JCO.2005.10.202. Epub 2005 Mar 14.
    Frei E 3rd, Elias A, Wheeler C, Richardson P, Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res. 1998 Sep;4(9):2027-37.
    Rashid MBMA, Toh TB, Hooi L, Silva A, Zhang Y, Tan PF, Teh AL, Karnani N, Jha S, Ho CM, Chng WJ, Ho D, Chow EK. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). Sci Transl Med. 2018 Aug 8;10(453):eaan0941. doi: 10.1126/scitranslmed.aan0941.
    de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, Braun TM, Nguyen HQ, Champlin R, Garcia-Manero G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010 Dec 1;116(23):5420-31. doi: 10.1002/cncr.25500. Epub 2010 Jul 29.
    Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 May 1;115(9):1899-905. doi: 10.1002/cncr.24198.
    Singal R, Ramachandran K, Gordian E, Quintero C, Zhao W, Reis IM. Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. Clin Genitourin Cancer. 2015 Feb;13(1):22-31. doi: 10.1016/j.clgc.2014.07.008. Epub 2014 Aug 1.
    Cohen AL, Ray A, Van Brocklin M, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT. A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. Oncotarget. 2016 Dec 26;8(32):52413-52419. doi: 10.18632/oncotarget.14183. eCollection 2017 Aug 8.
    Lee V, Wang J, Zahurak M, Gootjes E, Verheul HM, Parkinson R, Kerner Z, Sharma A, Rosner G, De Jesus-Acosta A, Laheru D, Le DT, Oganesian A, Lilly E, Brown T, Jones P, Baylin S, Ahuja N, Azad N. A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. Clin Cancer Res. 2018 Dec 15;24(24):6160-6167. doi: 10.1158/1078-0432.CCR-18-0421. Epub 2018 Aug 10.
    Sharma A, Vatapalli R, Abdelfatah E, Wyatt McMahon K, Kerner Z, A Guzzetta A, Singh J, Zahnow C, B Baylin S, Yerram S, Hu Y, Azad N, Ahuja N. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. PLoS One. 2017 Apr 26;12(4):e0176139. doi: 10.1371/journal.pone.0176139. eCollection 2017.
    Moro H, Hattori N, Nakamura Y, Kimura K, Imai T, Maeda M, Yashiro M, Ushijima T. Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways. Gastric Cancer. 2020 Jan;23(1):105-115. doi: 10.1007/s10120-019-01010-1. Epub 2019 Sep 25.
    Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970 Nov;30(11):2760-9. No abstract available.

  17. 17
  18. 18
  19. 19
  20. 20